You are here

FDA Advisory Committee Recommends Muraglitazar for the Treatment of Type 2 Diabetes as Monotherapy and in Combination With Metformin

PRINCETON, NEW JERSEY AND WHITEHOUSE STATION, NEW JERSEY (September 9, 2005) -- Bristol-Myers Squibb (NYSE: BMY) and Merck & Co., Inc. (NYSE: MRK) jointly announced today that the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee voted to recommend approval of Pargluva™ (muraglitazar), the companies' investigational oral medicine for the treatment of type 2 diabetes, for use as monotherapy and in combination with metformin. The committee voted not to recommend its use in combination with a sulfonylurea.

Bristol-Myers Squibb researchers presented the available pre-clinical and clinical data to support the benefit-risk profile of Pargluva and reviewed a comprehensive pharmacovigilance plan and outcomes evaluation in order to allow the therapeutic balance of Pargluva to be continually assessed going forward. The FDA is not bound by the committee's recommendation.

Pargluva is an investigational oral medication that, if approved, would become the first marketed agent in a new class of compounds called glitazars. Pargluva is a dual alpha/gamma PPAR (peroxisome proliferator-activated receptor) activator. Activation of PPAR-gamma is associated with reductions in plasma glucose levels, while activation of PPAR-alpha is associated with reductions in plasma triglyceride levels and increases in high-density lipoprotein, or "good" cholesterol (HDL-C) levels.

Bristol-Myers Squibb and Merck are collaborators in the global development and commercialization of Pargluva. The New Drug Application (NDA) for Pargluva was submitted to the FDA in late December 2004.

"Bristol-Myers Squibb and Merck are encouraged by this recommendation," said Elliott Sigal, M.D., Ph.D., chief scientific officer and president, Pharmaceutical Research Institute, Bristol-Myers Squibb. "We are committed to bringing important medicines to patients with type 2 diabetes and look forward to further discussions with the FDA."

Source: Bristol-Myers Squibb and Merck & Co., Inc.

Recent Headlines

WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs